Today, only six days after I originally purchased stock in King Pharmaceuticals Inc. (KG), the company announced that it has agreed to end its patent infringement lawsuit against CorePharma LLC relating to its important muscle relaxant drug Skelaxin. Under the agreement CorePharma will be allowed to make an authorized generic version of Metaxalone 800 mg, as well as CorePharma's generic 800 mg metaxalone product. The news immediately sent the stock up and I took this opportunistic exit with a 16.7% gain. The reason for exiting is that this type of an agreement is the only reasonable way this kind of dispute can be handled, so this should have been expected and does not materially change KG's position. In fact, the only thing that has changed is the short term perception of market participants, creating a short term supply/demand imbalance. I expect KG to continue going up, but now at a much slower pace and in spurts.